Qingqing Cai, MD. PhD.

CONTACT

Lead Sponsor

Sun Yat-sen University

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

No

•1. Aged ≥18,≤80 years, both male and female.
•2. Pathologically confirmed DLBCL
•3. No prior treatment for DLBCL.
•4. There must be at least one measurable or evaluable lesion that meets the evaluation criteria for Lugano 2014 lymphoma.
•5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-
•6. Expected survival ≥3 months.
•7. International Prognostic Index (IPI) ≤ 2
•8. Sufficient bone marrow, liver, and kidney function.

•1. Other types of LBCL:Primary Cutaneous Diffuse Large B-cell Lymphoma (Leg Type), Primary Mediastinal (Thymic) Large B-cell Lymphoma, Lymphomatoid Granulomatosis, ALK-positive Diffuse Large B-cell Lymphoma, Plasmablastic Lymphoma, Intravascular Large B-cell Lymphoma, T-cell/Histiocyte-rich Large B-cell Lymphoma, and others.
•2. Transformed DLBCL.
•3. Patients with central nervous system involvement, or those who require high-dose methotrexate for prevention.
•4. The patients had previously received antitumor therapy.
•5. Patients with the infection of human immunodeficiency virus (HIV) and/or acquired immunodeficiency syndrome.
•6. Pregnant and lactating women and subjects of childbearing age who do not want to use contraception.
•7. Mentally ill persons or persons unable to obtain informed consent.
•8. The investigators think that the patient is not suitable for the study.

Related studies

NCT06395103 · B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, and more

NCT07200375 · Diffuse Large B-Cell Lymphoma

NCT03223610 · Lymphoma, Non-Hodgkin Lymphoma, and more

NCT03418038 · Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, and more

NCT05272384 · Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, and more

Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL